Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
903.3 DKK | -1.05% | +2.28% | +29.39% |
06:01am | Genetic profile may predict best response to weight-loss drug Wegovy | RE |
17/05 | Roche: share price stands out, Deutsche Bank in support | CF |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+29.39% | 58TCr | |
+32.09% | 69TCr | |
-1.34% | 37TCr | |
+20.34% | 33TCr | |
+7.39% | 29TCr | |
+13.77% | 24TCr | |
-3.03% | 21TCr | |
+10.02% | 21TCr | |
+8.49% | 17TCr | |
-0.52% | 16TCr |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- INTERVIEW - Lars Fruergaard Jorgensen, CEO of Novo Nordisk: Treating obesity will be one of our top healthcare priorities